CuddihyRM, BorgmanSK. Considerations for diabetes: treatment with insulin pen devices. Am J Ther, 2013; 20: 694–702.
2.
AhmannA, et al.Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes. Diab Tech Ther, 2014; 16: 76–83.
3.
Tuan-MahmoodTM, et al.Micro needles for intradermal and transdermal drug delivery. Eur J Pharm Sci, 2013; 50: 623–37.
4.
HultströmM, et al.Intradermal Insulin Delivery: A Promising Future for Diabetes Management. JDST, 2014; 8: 453–57.
5.
YeagerHK, IgnautDA. Analysis and perspective of dosing accuracy and insulin flow rate characteristics of a new disposable insulin pen, FlexTouch, compared with SoloSTAR. J Diabetes Sci Technol, 2013; 7: 1027–29.
6.
SchaeferMK, et al.Sharing insulin pens: are you putting patients at risk?. Diabetes Care, 2013; 36: e188–89.
7.
SteinerS, et al.Technosphere/Insulin—proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endo Diab, 2002; 110: 17–21.
8.
HeinemannL, HeiseT. Current status of the development of inhaled insulin. Brit J Diab Vasc Dis, 2004; 4: 295–301.
9.
PetrakF, et al.Psychological insulin resistance in type 2 diabetes patients regarding oral antidiabetes treatment, subcutaneous insulin injections, or inhaled insulin. Diab Tech Ther, 2013; 15: 702–10.
10.
NavgireSD, et al.Recent patents on oral insulin delivery. Recent Pat Drug Deliv Formul, 2014. [Epub ahead of print]
11.
ZijlstraE, et al.Oral Insulin Reloaded: A Structured Approach. JDST, 2014; 8: 458–65.
